#leerink
Latest news and interesting information about leerink.
Leerink Reaffirms Eli Lilly Stock Rating on Gene Therapy
Leerink reaffirms Eli Lilly stock rating with Outperform and $1,119 target, citing promising gene therapy data from VERVE-102 trial. Bond.az covers the latest.
...
